The 3 case-control studies by Drs Rahme, Solomon, Watson, and their colleagues1- 3 published recently in the ARCHIVES suggest that the main reason for an increased risk of MI found for rofecoxib when compared with naproxen in the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial4 may be a cardioprotective effect of naproxen. We have 2 concerns with this interpretation.
Jüni P, Dieppe P, Egger M. Risk of Myocardial Infarction Associated With Selective COX-2 Inhibitors: Questions Remain. Arch Intern Med. 2002;162(22):2639. doi:
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.